kpcczКомплексные проблемы сердечно-сосудистых заболеванийComplex Issues of Cardiovascular Diseases2306-12782587-9537Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”10.17802/2306-1278-2023-12-4-149-162kpccz-1359Research ArticleАНАЛИТИЧЕСКИЙ ОБЗОР. КардиологияREVIEW. CardiologyБИОМАРКЕРЫ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ В ПЕДИАТРИЧЕСКОЙ ПРАКТИКЕBIOMARKERS OF HEART FAILURE IN PEDIATRIC PRACTICEhttps://orcid.org/0000-0001-6197-195XХамадьяноваАида УльфатовнаKhamadyanovaAida U.

кандидат медицинских наук доцент кафедры акушерства и гинекологии № 1 федерального государственного бюджетного образовательного учреждения высшего образования «Башкирский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Уфа, Российская Федерация

PhD, Associate Professor at the Department of Obstetrics and Gynecology No. 1, Bashkir State Medical University, Ufa, Russian Federation

vkomissiya@inbox.ruhttps://orcid.org/0009-0009-6822-8435ВалинуровАйрат РифовичValinurovAyrat R.

заведующий кардиологическим отделением общества с ограниченной ответственностью «Октябрьский сосудистый центр», Октябрьский, Российская Федерация

Head of the Cardiology Department of the Limited Liability Company “Oktyabrsky Vascular Center”, Oktyabrsky, Russian Federation

https://orcid.org/0000-0001-6407-3880ТрусовЮрий АлександровичTrusovYuri A.

врач-кардиолог, ассистент федерального государственного бюджетного образовательного учреждения высшего образования «Самарский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Самара, Российская Федерация

Cardiologist, Assistant, Federal State Budgetary Educational Institution of Higher Education “Samara State Medical University” of the Ministry of Healthcare of the Russian Federation, Samara, Russian Federation

https://orcid.org/0009-0009-2681-054XИгнатиковаЕкатерина ЕвгениевнаIgnatikovaEkaterina E.

студент института «Медицинская академия им. С.И. Георгиевского» федерального государственного автономного образовательного учреждения высшего образования «Крымский федеральный университет имени В.И. Вернадского», Симферополь, Российская Федерация

Student at the Institute “S.I. Georgievsky Medical Academy”, Federal State Autonomous Educational Institution of Higher Education “V.I. Vernadsky Crimean Federal University”, Simferopol, Russian Federation

https://orcid.org/0000-0002-6085-2673ПлечевВячеслав ВладимировичPlechevVyacheslav V.

студент федерального государственного бюджетного образовательного учреждения высшего образования «Башкирский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Уфа, Российская Федерация

Student at the Bashkir State Medical University, Ufa, Russian Federation

https://orcid.org/0000-0002-9087-4558НазмиеваКсения АлександровнаNazmievaKsenia A.

ассистент кафедры фармакологии федерального государственного бюджетного образовательного учреждения высшего образования «Башкирский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Уфа, Российская Федерация

Assistant at the Department of Pharmacology, Bashkir State Medical University, Ufa, Russian Federation

https://orcid.org/0009-0005-7668-3738ЗариповДанис ИльшатовичZaripovDanis I.

студент федерального государственного бюджетного образовательного учреждения высшего образования «Башкирский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Уфа, Российская Федерация

Student at the Bashkir State Medical University, Ufa, Russian Federation

https://orcid.org/0000-0001-5073-1766ТюшевскихЯна АлексеевнаTyushevskikhYana A.

студент федерального государственного бюджетного образовательного учреждения высшего образования «Башкирский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Уфа, Российская Федерация

Student at the Bashkir State Medical University, Ufa, Russian Federation

https://orcid.org/0009-0005-1335-4531БакиеваАлина РамилевнаBakievaAlina R.

студент федерального государственного бюджетного образовательного учреждения высшего образования «Башкирский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Уфа, Российская Федерация

Student at the Bashkir State Medical University, Ufa, Russian Federation

https://orcid.org/0009-0004-2565-1966НасибуллинаКарина ТимуровнаNasibullinaKarina T.

студент федерального государственного бюджетного образовательного учреждения высшего образования «Башкирский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Уфа, Российская Федерация

Student at the Bashkir State Medical University, Ufa, Russian Federation

https://orcid.org/0009-0002-7982-8654АрслановРуслан МаратовичArslanovRuslan M.

студент федерального государственного бюджетного образовательного учреждения высшего образования «Башкирский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Уфа, Российская Федерация

Student at the Bashkir State Medical University, Ufa, Russian Federation

https://orcid.org/0009-0005-3573-2003ЗиннуроваОлеся ЕвгеньевнаZinnurovaOlesya E.

студент федерального государственного бюджетного образовательного учреждения высшего образования «Башкирский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Уфа, Российская Федерация

Student at the Bashkir State Medical University, Ufa, Russian Federation

Федеральное государственное бюджетное образовательное учреждение высшего образования «Башкирский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Уфа, Российская ФедерацияРоссияBashkir State Medical University, Ufa, Russian FederationRussian FederationОбщество с ограниченной ответственностью «Октябрьский сосудистый центр», Октябрьский, Российская ФедерацияРоссияLimited Liability Company “Oktyabrsky Vascular Center”, Oktyabrsky, Russian FederationRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Самарский государственный медицинский университет» Министерства здравоохранения Российской Федерации, Самара, Российская ФедерацияРоссияFederal State Budgetary Educational Institution of Higher Education «Samara State Medical University» of the Ministry of Healthcare of the Russian Federation, Samara, Russian FederationRussian FederationФедеральное государственное автономное образовательное учреждение высшего образования «Крымский федеральный университет имени В.И. Вернадского», Симферополь, Российская ФедерацияРоссияFederal State Autonomous Educational Institution of Higher Education “V.I. Vernadsky Crimean Federal University”, Simferopol, Russian FederationRussian Federation202325122023124149162Copyright © Хамадьянова А.У., Валинуров А.Р., Трусов Ю.А., Игнатикова Е.Е., Плечев В.В., Назмиева К.А., Зарипов Д.И., Тюшевских Я.А., Бакиева А.Р., Насибуллина К.Т., Арсланов Р.М., Зиннурова О.Е., 20232023Хамадьянова А.У., Валинуров А.Р., Трусов Ю.А., Игнатикова Е.Е., Плечев В.В., Назмиева К.А., Зарипов Д.И., Тюшевских Я.А., Бакиева А.Р., Насибуллина К.Т., Арсланов Р.М., Зиннурова О.Е.Khamadyanova A.U., Valinurov A.R., Trusov Y.A., Ignatikova E.E., Plechev V.V., Nazmieva K.A., Zaripov D.I., Tyushevskikh Y.A., Bakieva A.R., Nasibullina K.T., Arslanov R.M., Zinnurova O.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nii-kpssz.com/jour/article/view/1359Основные положения

Основные положения

В педиатрии биомаркеры сердечной недостаточности особенно важны для раннего выявления и стратификации риска пациентов с системными заболеваниями и связанным с ними риском раннего развития сердечной недостаточности. Новые биомаркеры обладают определенными прогностическими преимуществами, но и некоторыми ограничениями, особенно в педиатрии из-за низкой специфичности и недостаточности данных о долгосрочном применении. Таким образом, прогностическая ценность этих биомаркеров полностью не подтверждена и требует дальнейшего изучения для широкого клинического применения.

 

 

Аннотация

Аннотация

Сердечная недостаточность (СН) у детей может развиваться по разным причинам, которые зависят от возраста. Например, в период новорожденности и в раннем возрасте главной причиной являются врожденные пороки сердца, кардиомиопатия и воспалительные заболевания сердца. У детей применение биомаркеров с целью диагностики СН оставалось в основном «научным» из-за различий в механизме, лежащем в основе сердечной дисфункции, а также из-за трудностей унификация ввиду влияния возраста на уровни исследуемых маркеров. Цель исследования – анализ литературы и систематизация биомаркеров в соответствии с патофизиологическими механизмами, способствующими развитию СН у детей. Авторы провели электронный поиск публикаций в базах данных PubMed, Google Scholar и eLIBRARY. Новые биомаркеры обладают определенными прогностическими преимуществами, но и некоторыми ограничениями, особенно в педиатрии из-за низкой специфичности и недостаточности данных о долгосрочном применении. Таким образом, прогностическая ценность этих биомаркеров полностью не подтверждена и требует дальнейшего изучения для широкого клинического применения. Панели с несколькими маркерами становятся все более многообещающими, однако для улучшения понимания индивидуальной терапии СН под контролем биомаркеров требуется больше клинических исследований.

HighlightsIn pediatrics, biomarkers of heart failure (HF) are particularly important for early detection and risk stratification of patients with systemic diseases and the associated risk of early development of HF. New biomarkers have certain prognostic advantages, but also some limitations, especially in pediatrics due to low specificity and insufficient data on long-term use. Thus, the prognostic value of these biomarkers has not been fully confirmed and requires further study for wide clinical use.Abstract

Heart failure (HF) in children can develop for various reasons, which depend on the age of the patient. For example, during the neonatal period and at an early age, the main cause is congenital heart defects, cardiomyopathy and inflammatory heart diseases. In children, the use of biomarkers for the diagnosis of HF remained mostly “scientific” due to differences in the mechanism underlying cardiac dysfunction, as well as due to the difficulties of unification due to the influence of age on the levels of the markers studied. The aim of the study is to analyze the literature and systematize biomarkers in accordance with the pathophysiological mechanisms that contribute to the development of HF in children. The authors conducted a search for publications in the PubMed, Google Scholar and eLibrary databases. New biomarkers have certain prognostic advantages, but also some limitations, especially in pediatrics due to low specificity and insufficient data on long-term use. Thus, the prognostic value of these biomarkers has not been fully confirmed and requires further study for wide clinical use. Panels with multiple markers are becoming more promising, however, more clinical studies are needed to improve the understanding of biomarker-guided therapy for HF.

Сердечная недостаточностьБиомаркерыПедиатрияДетиПрогнозЛечениеHeart failureBiomarkersPediatricsChildrenPrognosisTreatmentАвторы заявляют об отсутствии финансирования исследования.ReferencesKirk R, Dipchand AI, Rosenthal DN, Addonizio L, Burch M, Chrisant M, Dubin A, Everitt M, Gajarski R, Mertens L, Miyamoto S, Morales D, Pahl E, Shaddy R, Towbin J, Weintraub R. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. [Corrected]. J Heart Lung Transplant. 2014;33(9):888-909. doi: 10.1016/j.healun.2014.06.002.Kirk R, Dipchand AI, Rosenthal DN, Addonizio L, Burch M, Chrisant M, Dubin A, Everitt M, Gajarski R, Mertens L, Miyamoto S, Morales D, Pahl E, Shaddy R, Towbin J, Weintraub R. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. [Corrected]. J Heart Lung Transplant. 2014;33(9):888-909. doi: 10.1016/j.healun.2014.06.002.Абарова А.А., Малик В.И., Турмова Е.П. Особенности развития сердечной недостаточности у детей. International journal of professional science. 2022; (11-1): 80-85.Abarova AA, Malik VI., Turmova EP. Features of the development of heart failure in children. International Journal of Professional Science. 2022; (11-1): 80-85. (In Russian).Senekovič Kojc T, Marčun Varda N. Novel Biomarkers of Heart Failure in Pediatrics. Children (Basel). 2022;9(5):740. doi: 10.3390/children9050740.Senekovič Kojc T, Marčun Varda N. Novel Biomarkers of Heart Failure in Pediatrics. Children (Basel). 2022;9(5):740. doi: 10.3390/children9050740.Российское кардиологическое общество (РКО) . Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. doi:10.15829/1560-4071-2020-4083Russian Society of Cardiology (RKO). Chronic heart failure. Clinical Guidelines 2020. Russian Journal of Cardiology. 2020;25(11):4083. doi:10.15829/1560-4071-2020-4083 (In Russian).Агеев Ф.Т., Овчинников А.Г. Диастолическая сердечная недостаточность: 20 лет спустя. Актуальные вопросы патогенеза, диагностики и лечения сердечной недостаточности с сохраненной ФВ ЛЖ. Кардиология. 2023;63(3):3-12. doi:10.18087/cardio.2023.3.n2376Ageev FT., Ovchinnikov AG. Diastolic heart failure: 20 years later. Topical issues of pathogenesis, diagnosis and treatment of heart failure with preserved LV LV. Cardiology. 2023;63(3):3-12. doi:10.18087/cardio.2023.3.n2376 (In Russian)Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ. Cardiac natriuretic peptides. Nat Rev Cardiol. 2020;17(11):698-717. doi: 10.1038/s41569-020-0381-0.Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ. Cardiac natriuretic peptides. Nat Rev Cardiol. 2020;17(11):698-717. doi: 10.1038/s41569-020-0381-0.Шарипов А., Алимов А., Усманов Р., Расулов А., Шорахмедов, Ш.. Диагностическое значение натрийуретического пептида при сердечной недостаточности у детей с врожденными пороками сердца . in Library. 2023; 1(1): 267–271.Sharipov A., Alimov A., Usmanov R., Rasulov A., Shorakhmedov, Sh.. Diagnostic value of natriuretic peptide in heart failure in children with congenital heart defects. in Library. 2023; 1(1): 267–271.Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018;12:2. doi: 10.1186/s13036-017-0093-0.Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018;12:2. doi: 10.1186/s13036-017-0093-0. (In Russian)Nakagawa Y, Nishikimi T, Kuwahara K. Atrial and brain natriuretic peptides: Hormones secreted from the heart. Peptides. 2019;111:18-25. doi: 10.1016/j.peptides.2018.05.012.Nakagawa Y, Nishikimi T, Kuwahara K. Atrial and brain natriuretic peptides: Hormones secreted from the heart. Peptides. 2019;111:18-25. doi: 10.1016/j.peptides.2018.05.012.Kiess A, Green J, Willenberg A, Ceglarek U, Dähnert I, Jurkutat A, Körner A, Hiemisch A, Kiess W, Vogel M. Age-Dependent Reference Values for hs-Troponin T and NT-proBNP and Determining Factors in a Cohort of Healthy Children (The LIFE Child Study). Pediatr Cardiol. 2022;43(5):1071-1083. doi: 10.1007/s00246-022-02827-x.Kiess A, Green J, Willenberg A, Ceglarek U, Dähnert I, Jurkutat A, Körner A, Hiemisch A, Kiess W, Vogel M. Age-Dependent Reference Values for hs-Troponin T and NT-proBNP and Determining Factors in a Cohort of Healthy Children (The LIFE Child Study). Pediatr Cardiol. 2022;43(5):1071-1083. doi: 10.1007/s00246-022-02827-x.Albers S, Mir T, Haddad M, Läer S. N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clinical Chemistry and Laboratory Medicine (CCLM). 2006;44(1): 80-85. doi:10.1515/CCLM.2006.016Albers S, Mir T, Haddad M, Läer S. N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clinical Chemistry and Laboratory Medicine (CCLM). 2006;44(1): 80-85. doi:10.1515/CCLM.2006.016Kiess A, Green J, Willenberg A, Ceglarek U, Dähnert I, Jurkutat A, Körner A, Hiemisch A, Kiess W, Vogel M. Age-Dependent Reference Values for hs-Troponin T and NT-proBNP and Determining Factors in a Cohort of Healthy Children (The LIFE Child Study). Pediatr Cardiol. 2022;43(5):1071-1083. doi: 10.1007/s00246-022-02827-x.Kiess A, Green J, Willenberg A, Ceglarek U, Dähnert I, Jurkutat A, Körner A, Hiemisch A, Kiess W, Vogel M. Age-Dependent Reference Values for hs-Troponin T and NT-proBNP and Determining Factors in a Cohort of Healthy Children (The LIFE Child Study). Pediatr Cardiol. 2022;43(5):1071-1083. doi: 10.1007/s00246-022-02827-x.Pervez MO, Winther JA, Brynildsen J, Strand H, Christensen G, Høiseth AD, Myhre PL, Røysland R, Lyngbakken MN, Omland T, Røsjø H. Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study. Biomarkers. 2018;23(7):654-663. doi: 10.1080/1354750X.2018.1474258Pervez MO, Winther JA, Brynildsen J, Strand H, Christensen G, Høiseth AD, Myhre PL, Røysland R, Lyngbakken MN, Omland T, Røsjø H. Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study. Biomarkers. 2018;23(7):654-663. doi: 10.1080/1354750X.2018.1474258Çavuşoğlu Y, Alper AT, Altay H, Çelik A, Demirkan B, Güvenç TS, Küçükoğlu MS, Nalbantgil S, Özdemir M, Özin B, Sayın T, Yıldırımtürk Ö, Yılmaz MB, Zorkun C. Natriuretic Peptides in Clinical Practice. Anatol J Cardiol. 2019;21(1):1-40. doi: 10.14744/AnatolJCardiol.2019.55623.Çavuşoğlu Y, Alper AT, Altay H, Çelik A, Demirkan B, Güvenç TS, Küçükoğlu MS, Nalbantgil S, Özdemir M, Özin B, Sayın T, Yıldırımtürk Ö, Yılmaz MB, Zorkun C. Natriuretic Peptides in Clinical Practice. Anatol J Cardiol. 2019;21(1):1-40. doi: 10.14744/AnatolJCardiol.2019.55623.Omran F, Kyrou I, Osman F, Lim VG, Randeva HS, Chatha K. Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future. Int J Mol Sci. 2022;23(10):5680. doi: 10.3390/ijms23105680.Omran F, Kyrou I, Osman F, Lim VG, Randeva HS, Chatha K. Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future. Int J Mol Sci. 2022;23(10):5680. doi: 10.3390/ijms23105680.Dhingra R, Vasan RS. Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. Trends Cardiovasc Med. 2017;27(2):123-133. doi: 10.1016/j.tcm.2016.07.005.Dhingra R, Vasan RS. Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. Trends Cardiovasc Med. 2017;27(2):123-133. doi: 10.1016/j.tcm.2016.07.005.Bobillo-Perez S, Girona-Alarcon M, Corniero P, Sole-Ribalta A, Balaguer M, Esteban E, Valls A, Jordan I, Cambra FJ. Pro-atrial natriuretic peptide and pro-adrenomedullin before cardiac surgery in children. Can we predict the future? PLoS One. 2020;15(7):e0236377. doi: 10.1371/journal.pone.0236377.Bobillo-Perez S, Girona-Alarcon M, Corniero P, Sole-Ribalta A, Balaguer M, Esteban E, Valls A, Jordan I, Cambra FJ. Pro-atrial natriuretic peptide and pro-adrenomedullin before cardiac surgery in children. Can we predict the future? PLoS One. 2020;15(7):e0236377. doi: 10.1371/journal.pone.0236377.Kotby AA, Taman KH, Sedky HT, Habeeb NM, El-Hadidi ES, Yosseif HS. Atrial natriuretic peptide as a marker of heart failure in children with left ventricular volume overload. J Paediatr Child Health. 2013;49(1):43-47. doi: 10.1111/jpc.12012.Kotby AA, Taman KH, Sedky HT, Habeeb NM, El-Hadidi ES, Yosseif HS. Atrial natriuretic peptide as a marker of heart failure in children with left ventricular volume overload. J Paediatr Child Health. 2013;49(1):43-47. doi: 10.1111/jpc.12012.Del Re DP, Amgalan D, Linkermann A, Liu Q, Kitsis RN. Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease. Physiol Rev. 2019;99(4):1765-1817. doi: 10.1152/physrev.00022.2018.Del Re DP, Amgalan D, Linkermann A, Liu Q, Kitsis RN. Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease. Physiol Rev. 2019;99(4):1765-1817. doi: 10.1152/physrev.00022.2018.Чаулин А.М., Дупляков Д.В. Высокочувствительные сердечные тропонины: циркадные ритмы. Кардиоваскулярная терапия и профилактика. 2021;20(1):2639. doi:10.15829/1728-8800-2021-2639Chaulin A.M., Duplyakov D.V. Highly sensitive cardiac troponins: circadian rhythms. Cardiovascular therapy and prevention. 2021;20(1):2639. doi:10.15829/1728-8800-2021-2639 (In Russian)Халиков А.А., Кузнецов К.О., Искужина Л.Р., Халикова Л.В. Судебно-медицинские аспекты внезапной аутопсия-отрицательной сердечной смерти. Судебно-медицинская экспертиза. 2021;64(3):59 63. doi:10.17116/sudmed20216403159Khalikov AA., Kuznetsov KO., Iskuzhina LR., Khalikova LV. Forensic aspects of sudden autopsy of negative cardiac death. Sudebno-meditsinskaya ekspertiza. 2021;64(3):59 63. doi:10.17116/sudmed20216403159 (In Russian)Ilva T, Lassus J, Siirilä-Waris K, Melin J, Peuhkurinen K, Pulkki K, Nieminen MS, Mustonen H, Porela P, Harjola VP. Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail. 2008;10(8):772-779. doi: 10.1016/j.ejheart.2008.06.009.Ilva T, Lassus J, Siirilä-Waris K, Melin J, Peuhkurinen K, Pulkki K, Nieminen MS, Mustonen H, Porela P, Harjola VP. Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail. 2008;10(8):772-779. doi: 10.1016/j.ejheart.2008.06.009.Torre M, Jarolim P. Cardiac troponin assays in the management of heart failure. Clin Chim Acta 2015; 441: 92–98. doi: 10.1016/j.cca.2014.12.027.Torre M, Jarolim P. Cardiac troponin assays in the management of heart failure. Clin Chim Acta 2015; 441: 92–98. doi: 10.1016/j.cca.2014.12.027.Uner A, Doğan M, Ay M, Acar C. The evaluation of serum N-terminal prohormone brain-type natriuretic peptide, troponin-I, and high-sensitivity C-reactive protein levels in children with congenital heart disease. Hum Exp Toxicol. 2014;33(11):1158-1166. doi: 10.1177/0960327113514097.Uner A, Doğan M, Ay M, Acar C. The evaluation of serum N-terminal prohormone brain-type natriuretic peptide, troponin-I, and high-sensitivity C-reactive protein levels in children with congenital heart disease. Hum Exp Toxicol. 2014;33(11):1158-1166. doi: 10.1177/0960327113514097.Zhou FJ, Zhou CY, Tian YJ, Xiao AJ, Li PL, Wang YH, Jia JW. Diagnostic value of analysis of H-FABP, NT-proBNP, and cTnI in heart function in children with congenital heart disease and pneumonia. Eur Rev Med Pharmacol Sci. 2014;18(10):1513-1516.Zhou FJ, Zhou CY, Tian YJ, Xiao AJ, Li PL, Wang YH, Jia JW. Diagnostic value of analysis of H-FABP, NT-proBNP, and cTnI in heart function in children with congenital heart disease and pneumonia. Eur Rev Med Pharmacol Sci. 2014;18(10):1513-1516.Shah A, Feraco AM, Harmon C, Tacy T, Fineman JR, Bernstein HS. Usefulness of various plasma biomarkers for diagnosis of heart failure in children with single ventricle physiology. Am J Cardiol. 2009;104(9):1280-1284. doi: 10.1016/j.amjcard.2009.06.046.Shah A, Feraco AM, Harmon C, Tacy T, Fineman JR, Bernstein HS. Usefulness of various plasma biomarkers for diagnosis of heart failure in children with single ventricle physiology. Am J Cardiol. 2009;104(9):1280-1284. doi: 10.1016/j.amjcard.2009.06.046.Sugimoto M, Ota K, Kajihama A, Nakau K, Manabe H, Kajino H. Volume overload and pressure overload due to left-to-right shunt-induced myo- cardial injury. Evaluation using a highly sensitive cardiac Troponin-I assay in children with congenital heart disease. Circ J 2011; 75: 2213–2219.Sugimoto M, Ota K, Kajihama A, Nakau K, Manabe H, Kajino H. Volume overload and pressure overload due to left-to-right shunt-induced myo- cardial injury. Evaluation using a highly sensitive cardiac Troponin-I assay in children with congenital heart disease. Circ J 2011; 75: 2213–2219.Kotby AA, Abd Al Aziz MM, Husseiny AH, Al-Fahham MM. Detection of Early Myocardial Injury in Children with Ventricular Septal Defect Using Cardiac Troponin I and Two-Dimensional Speckle Tracking Echocardiography. Pediatr Cardiol. 2020;41(8):1548-1558. doi: 10.1007/s00246-020-02410-2.Kotby AA, Abd Al Aziz MM, Husseiny AH, Al-Fahham MM. Detection of Early Myocardial Injury in Children with Ventricular Septal Defect Using Cardiac Troponin I and Two-Dimensional Speckle Tracking Echocardiography. Pediatr Cardiol. 2020;41(8):1548-1558. doi: 10.1007/s00246-020-02410-2.Kayali S, Ertugrul I, Yoldas T, Kaya O, Ozgür S, Orün UA, Karademir S. Sensitive Cardiac Troponins: Could They Be New Biomarkers in Pediatric Pulmonary Hypertension Due to Congenital Heart Disease? Pediatr Cardiol. 2018;39(4):718-725. doi: 10.1007/s00246-018-1811-1.Kayali S, Ertugrul I, Yoldas T, Kaya O, Ozgür S, Orün UA, Karademir S. Sensitive Cardiac Troponins: Could They Be New Biomarkers in Pediatric Pulmonary Hypertension Due to Congenital Heart Disease? Pediatr Cardiol. 2018;39(4):718-725. doi: 10.1007/s00246-018-1811-1.Cheung YF, Li VW, Lai CT, Shin VY, Keung W, Cheuk DK, Kwong A, Li RA, Chan GC. Circulating high-sensitivity troponin T and microRNAs as markers of myocardial damage during childhood leukaemia treatment. Pediatr Res. 2021;89(5):1245-1252. doi: 10.1038/s41390-020-1049-5.Cheung YF, Li VW, Lai CT, Shin VY, Keung W, Cheuk DK, Kwong A, Li RA, Chan GC. Circulating high-sensitivity troponin T and microRNAs as markers of myocardial damage during childhood leukaemia treatment. Pediatr Res. 2021;89(5):1245-1252. doi: 10.1038/s41390-020-1049-5.Алиева А.М., Байкова И.Е., Резник Е.В., Т.В. Пинчук, Л.М. Шнахова, Р.К. Валиев, М.Н. Сарыев, А.М. Рахаев, И.В. Ковтюх, И.Г. Никитин. Сердечный белок, связывающий жирные кислоты, — перспективный биологический маркер при сердечной недостаточности. РМЖ. Медицинское обозрение. 2022;6(1):5-11. doi: 10.32364/2587-6821-2022-6-1-5-11.Alieva A.M., Baykova I.E., Reznik E.V., T.V. Pinchuk, L.M. Shnakhova, R.K. Valiev, M.N. Sarychev, A.M. Rakhaev, I.V. Kovtyukh, I.G. Nikitin. Cardiac protein binding fatty acids is a promising biological marker for heart failure. breast cancer. Medical review. 2022;6(1):5-11. doi: 10.32364/2587-6821-2022-6-1-5-11. (In Russian)Jaiswal A, Vamne A, Verma MK, Doctor B. H-FABP as a diagnostic marker for early detection of young myocardial infarction among Indians. Bioinformation. 2022;18(6):506-512. doi: 10.6026/97320630018506.Jaiswal A, Vamne A, Verma MK, Doctor B. H-FABP as a diagnostic marker for early detection of young myocardial infarction among Indians. Bioinformation. 2022;18(6):506-512. doi: 10.6026/97320630018506.Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, Simic D, Radovanovic S, Simic T. Novel Biomarkers of Heart Failure. Adv Clin Chem. 2017;79:93-152. doi: 10.1016/bs.acc.2016.09.002.Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, Simic D, Radovanovic S, Simic T. Novel Biomarkers of Heart Failure. Adv Clin Chem. 2017;79:93-152. doi: 10.1016/bs.acc.2016.09.002.Rezar R, Jirak P, Gschwandtner M, Derler R, Felder TK, Haslinger M, Kopp K, Seelmaier C, Granitz C, Hoppe UC, Lichtenauer M. Heart-Type Fatty Acid-Binding Protein (H-FABP) and its Role as a Biomarker in Heart Failure: What Do We Know So Far? J Clin Med. 2020;9(1):164. doi: 10.3390/jcm9010164.Rezar R, Jirak P, Gschwandtner M, Derler R, Felder TK, Haslinger M, Kopp K, Seelmaier C, Granitz C, Hoppe UC, Lichtenauer M. Heart-Type Fatty Acid-Binding Protein (H-FABP) and its Role as a Biomarker in Heart Failure: What Do We Know So Far? J Clin Med. 2020;9(1):164. doi: 10.3390/jcm9010164.Russell TM, Richardson DR. The good Samaritan glutathione-S-transferase P1: An evolving relationship in nitric oxide metabolism mediated by the direct interactions between multiple effector molecules. Redox Biol. 2023;59:102568. doi: 10.1016/j.redox.2022.102568.Russell TM, Richardson DR. The good Samaritan glutathione-S-transferase P1: An evolving relationship in nitric oxide metabolism mediated by the direct interactions between multiple effector molecules. Redox Biol. 2023;59:102568. doi: 10.1016/j.redox.2022.102568.Andrukhova O, Salama M, Rosenhek R, Gmeiner M, Perkmann T, Steindl J, Aharinejad S. Serum glutathione S-transferase P1 1 in prediction of cardiac function. J Card Fail.;18(3):253-61. doi: 10.1016/j.cardfail.2011.11.003Andrukhova O, Salama M, Rosenhek R, Gmeiner M, Perkmann T, Steindl J, Aharinejad S. Serum glutathione S-transferase P1 1 in prediction of cardiac function. J Card Fail.;18(3):253-61. doi: 10.1016/j.cardfail.2011.11.003Tripaydonis A, Conyers R, Elliott DA. Pediatric Anthracycline-Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling. Clin Pharmacol Ther. 2019;105(3):614-624. doi: 10.1002/cpt.1311.Tripaydonis A, Conyers R, Elliott DA. Pediatric Anthracycline-Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling. Clin Pharmacol Ther. 2019;105(3):614-624. doi: 10.1002/cpt.1311.Яфарова А.А., Киселев А.Р., Шептулина А.Ф., Драпкина О.М. Современные представления о роли галанинергической системы в патогенезе сердечной недостаточности и ремоделирования миокарда. Кардиоваскулярная терапия и профилактика. 2023;22(5):3546. doi:10.15829/1728-8800-2023-3546Yafarova A.A., Kiselev A.R., Sheptulina A.F., Drapkina O.M. Modern ideas about the role of the galaninergic system in the pathogenesis of heart failure and myocardial remodeling. Cardiovascular therapy and prevention. 2023;22(5):3546. doi:10.15829/1728-8800-2023-3546 (In Russian)Алиева АМ, Байкова ИЕ, Кисляков ВА, Гасанова ЭТ, Алмазова ИИ, Пинчук ТВ, Федулаев ЮН, Жбанов ИВ, Перевертов ВА, Ковтюх ИВ, Никитин ИГ, Резник ЕВ. Галектин-3: диагностическая и прогностическая ценность определения у пациентов с хронической сердечной недостаточностью.Терапевтический архив. 2019;91(9):145-149. doi: 10.26442/00403660.2019.09.000226Alieva A M, Baykova I E, Kislyakov V A, Hasanova ET, Almazova I, Pinchuk TV, Fedulaev Yu N, Zhbanov I V, Perevertov VA, Kovtyukh I V, Nikitin IG, Reznik EV. Galectin-3: diagnostic and prognostic value of determination in patients with chronic heart failure.Therapeutic Archive. 2019;91(9):145-149. doi: 10.26442/00403660.2019.09.000226 (In Russian)Saleh N, Khattab A, Rizk M, Salem S, Abo-Haded H. Value of Galectin-3 assay in children with heart failure secondary to congenital heart diseases: a prospective study. BMC Paediatr 2020; 20: 537. doi: 10.1186/s12887- 020-02427-9.Saleh N, Khattab A, Rizk M, Salem S, Abo-Haded H. Value of Galectin-3 assay in children with heart failure secondary to congenital heart diseases: a prospective study. BMC Paediatr 2020; 20: 537. doi: 10.1186/s12887- 020-02427-9.Gocer H, Günday M, Ünal M. Plasma galectin-3 as a biomarker for clinical staging of heart failure: a cross-sectional evaluation of 100 cases. Clin Ter. 2019;170(4):267-271. doi: 10.7417/CT.2019.2146.Gocer H, Günday M, Ünal M. Plasma galectin-3 as a biomarker for clinical staging of heart failure: a cross-sectional evaluation of 100 cases. Clin Ter. 2019;170(4):267-271. doi: 10.7417/CT.2019.2146.McGinn C, Casey FA, Watson C, Morrison L. Paediatric heart failure - understanding the pathophysiology and the current role of cardiac biomarkers in clinical practice. Cardiol Young. 2023;33(4):503-513. doi: 10.1017/S1047951123000331.McGinn C, Casey FA, Watson C, Morrison L. Paediatric heart failure - understanding the pathophysiology and the current role of cardiac biomarkers in clinical practice. Cardiol Young. 2023;33(4):503-513. doi: 10.1017/S1047951123000331.Kotby AA, Youssef OI, Elmaraghy MO, El Sharkawy OS. Galectin-3 in Children with Chronic Heart Failure with Normal and Reduced Ejection Fraction: Relationship to Disease Severity. Pediatr Cardiol. 2017;38(1):95-102. doi: 10.1007/s00246-016-1488-2.Kotby AA, Youssef OI, Elmaraghy MO, El Sharkawy OS. Galectin-3 in Children with Chronic Heart Failure with Normal and Reduced Ejection Fraction: Relationship to Disease Severity. Pediatr Cardiol. 2017;38(1):95-102. doi: 10.1007/s00246-016-1488-2.Фетисова В.И., Намитоков А.М., Гилевич И.В., Космачева Е.Д. Растворимый белок подавления онкогенности (sST2) в качестве возможного биомаркера у пациентов с острым коронарным синдромом. Южно-Российский журнал терапевтической практики. 2023;4(2):7-17. doi:10.21886/2712-8156-2023-4-2-7-17Fetisova V.I., Namitokov A.M., Gilevich I.V., Kosmacheva E.D. Soluble oncogenicity suppression protein (sST2) as a possible biomarker in patients with acute coronary syndrome. South-Russian Journal of Therapeutic Practice. 2023;4(2):7-17. doi:10.21886/2712-8156-2023-4-2-7-17 (In Russian).Bi J, Garg V, Yates AR. Galectin-3 and sST2 as Prognosticators for Heart Failure Requiring Extracorporeal Life Support: Jack n' Jill. Biomolecules. 2021;11(2):166. doi: 10.3390/biom11020166.Bi J, Garg V, Yates AR. Galectin-3 and sST2 as Prognosticators for Heart Failure Requiring Extracorporeal Life Support: Jack n' Jill. Biomolecules. 2021;11(2):166. doi: 10.3390/biom11020166.Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, Caravaca-Pérez P, Conde-Martel A, Crespo-Leiro MG, Delgado JF, Díez J, Formiga F, Manito N. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med. 2021;8:754499. doi: 10.3389/fcvm.2021.754499.Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, Caravaca-Pérez P, Conde-Martel A, Crespo-Leiro MG, Delgado JF, Díez J, Formiga F, Manito N. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med. 2021;8:754499. doi: 10.3389/fcvm.2021.754499.Aimo A, Georgiopoulos G, Senni M, Emdin M. Searching for diagnostic biomarkers of heart failure with preserved ejection fraction: methodological issues. Eur J Heart Fail. 2020;22(9):1598-1599. doi: 10.1002/ejhf.1977.Aimo A, Georgiopoulos G, Senni M, Emdin M. Searching for diagnostic biomarkers of heart failure with preserved ejection fraction: methodological issues. Eur J Heart Fail. 2020;22(9):1598-1599. doi: 10.1002/ejhf.1977.Ragusa R, Prontera C, Di Molfetta A, Cabiati M, Masotti S, Del Ry S, Amodeo A, Trivella MG, Clerico A, Caselli C. Time-course of circulating cardiac and inflammatory biomarkers after Ventricular Assist Device implantation: Comparison between paediatric and adult patients. Clin Chim Acta. 2018;486:88-93. doi: 10.1016/j.cca.2018.07.036.Ragusa R, Prontera C, Di Molfetta A, Cabiati M, Masotti S, Del Ry S, Amodeo A, Trivella MG, Clerico A, Caselli C. Time-course of circulating cardiac and inflammatory biomarkers after Ventricular Assist Device implantation: Comparison between paediatric and adult patients. Clin Chim Acta. 2018;486:88-93. doi: 10.1016/j.cca.2018.07.036.Hauser JA, Demyanets S, Rusai K, Goritschan C, Weber M, Panesar D, Rindler L, Taylor AM, Marculescu R, Burch M, Wojta J, Michel-Behnke I. Diagnostic performance and reference values of novel biomarkers of paediatric heart failure. Heart. 2016;102(20):1633-1639. doi: 10.1136/heartjnl-2016-309460.Hauser JA, Demyanets S, Rusai K, Goritschan C, Weber M, Panesar D, Rindler L, Taylor AM, Marculescu R, Burch M, Wojta J, Michel-Behnke I. Diagnostic performance and reference values of novel biomarkers of paediatric heart failure. Heart. 2016;102(20):1633-1639. doi: 10.1136/heartjnl-2016-309460.van den Bosch E, Bossers SSM, Kamphuis VP, Boersma E, Roos-Hesselink JW, Breur JMPJ, Ten Harkel ADJ, Kapusta L, Bartelds B, Roest AAW, Kuipers IM, Blom NA, Koopman LP, Helbing WA. Associations Between Blood Biomarkers, Cardiac Function, and Adverse Outcome in a Young Fontan Cohort. J Am Heart Assoc. 2021;10(5):e015022. doi: 10.1161/JAHA.119.015022.van den Bosch E, Bossers SSM, Kamphuis VP, Boersma E, Roos-Hesselink JW, Breur JMPJ, Ten Harkel ADJ, Kapusta L, Bartelds B, Roest AAW, Kuipers IM, Blom NA, Koopman LP, Helbing WA. Associations Between Blood Biomarkers, Cardiac Function, and Adverse Outcome in a Young Fontan Cohort. J Am Heart Assoc. 2021;10(5):e015022. doi: 10.1161/JAHA.119.015022.Ghelani SJ, Opotowsky AR, Harrild DM, Powell AJ, Azcue N, Ahmad S, Clair NS, Bradwin G, Rathod RH. Characterization of Circulating and Urinary Biomarkers in the Fontan Circulation and Their Correlation With Cardiac Imaging. Am J Cardiol. 2022;162:177-183. doi: 10.1016/j.amjcard.2021.08.06.Ghelani SJ, Opotowsky AR, Harrild DM, Powell AJ, Azcue N, Ahmad S, Clair NS, Bradwin G, Rathod RH. Characterization of Circulating and Urinary Biomarkers in the Fontan Circulation and Their Correlation With Cardiac Imaging. Am J Cardiol. 2022;162:177-183. doi: 10.1016/j.amjcard.2021.08.06.Халиков АА, Кильдюшов ЕМ, Кузнецов КО, Искужина ЛР, Рахматуллина ГР. Использование микроРНК с целью определения давности наступления смерти: обзор. Судебная медицина. 2021;7(3):132-138. doi: 10.17816/fm412Khalikov A, Kildyushov EM, Kuznetsov KO, Iskuzhina LR, Rakhmatullina GR. The use of microRNAs to determine the prescription of death: an overview. Forensic medicine. 2021;7(3):132-138. doi: 10.17816/fm412. (In Russian)Berezin AE. Circulating Biomarkers in Heart Failure. Adv Exp Med Biol. 2018;1067:89-108. doi: 10.1007/5584_2017_140.Berezin AE. Circulating Biomarkers in Heart Failure. Adv Exp Med Biol. 2018;1067:89-108. doi: 10.1007/5584_2017_140.Watson CJ, Gupta SK, O'Connell E, Thum S, Glezeva N, Fendrich J, Gallagher J, Ledwidge M, Grote-Levi L, McDonald K, Thum T. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail. 2015;17(4):405-15. doi: 10.1002/ejhf.244.Watson CJ, Gupta SK, O'Connell E, Thum S, Glezeva N, Fendrich J, Gallagher J, Ledwidge M, Grote-Levi L, McDonald K, Thum T. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail. 2015;17(4):405-15. doi: 10.1002/ejhf.244.Miyamoto SD, Karimpour-Fard A, Peterson V, Auerbach SR, Stenmark KR, Stauffer BL, Sucharov CC. Circulating microRNA as a biomarker for recovery in pediatric dilated cardiomyopathy. J Heart Lung Transplant. 2015;34(5):724-33. doi: 10.1016/j.healun.2015.01.979.Miyamoto SD, Karimpour-Fard A, Peterson V, Auerbach SR, Stenmark KR, Stauffer BL, Sucharov CC. Circulating microRNA as a biomarker for recovery in pediatric dilated cardiomyopathy. J Heart Lung Transplant. 2015;34(5):724-33. doi: 10.1016/j.healun.2015.01.979.Liu Y, Guan S, Xu H, Zhang N, Huang M, Liu Z. Inflammation biomarkers are associated with the incidence of cardiovascular disease: a meta-analysis. Front Cardiovasc Med. 2023;10:1175174. doi: 10.3389/fcvm.2023.1175174.Liu Y, Guan S, Xu H, Zhang N, Huang M, Liu Z. Inflammation biomarkers are associated with the incidence of cardiovascular disease: a meta-analysis. Front Cardiovasc Med. 2023;10:1175174. doi: 10.3389/fcvm.2023.1175174.Алиева А.М., Резник Е.В., Пинчук Т.В., Аракелян Р.А., Валиев Р.К., Рахаев А.М., Тихомирова А.С., Никитин И.Г. Фактор дифференцировки роста-15 (GDF-15) как биологический маркер при сердечной недостаточности. Архивъ внутренней медицины. 2023;13(1):14-23. doi:10.20514/2226-6704-2023-13-1-14-23.Alieva A.M., Reznik E.V., Pinchuk T.V., Arakelyan R.A., Valiev R.K., Rakhaev A.M., Tikhomirova A.S., Nikitin I.G. Growth differentiation factor-15 (GDF-15) as a biological marker in heart failure. Archive of Internal Medicine. 2023;13(1):14-23. doi:10.20514/2226-6704-2023-13-1-14-23. (In Russian)Stahrenberg R, Edelmann F, Mende M, Kockskämper A, Düngen HD, Lüers C, Binder L, Herrmann-Lingen C, Gelbrich G, Hasenfuss G, Pieske B, Wachter R. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail. 2010;12(12):1309-16. doi: 10.1093/eurjhf/hfq151.Stahrenberg R, Edelmann F, Mende M, Kockskämper A, Düngen HD, Lüers C, Binder L, Herrmann-Lingen C, Gelbrich G, Hasenfuss G, Pieske B, Wachter R. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail. 2010;12(12):1309-16. doi: 10.1093/eurjhf/hfq151.Cheung CL, Tan KCB, Au PCM, Li GHY, Cheung BMY. Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: A Mendelian randomization study. EBioMedicine. 2019;41:85-90. doi: 10.1016/j.ebiom.2019.02.021.Cheung CL, Tan KCB, Au PCM, Li GHY, Cheung BMY. Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: A Mendelian randomization study. EBioMedicine. 2019;41:85-90. doi: 10.1016/j.ebiom.2019.02.021.Zhou XJ, Zhang X, Zhang J, Zhou L, Zhou TT, Zhang JW. Diagnostic value of growth differentiation factor-15 and β2-microglobulin in children with congenital heart disease combined with chronic heart failure and its relationship with cardiac function. Eur Rev Med Pharmacol Sci. 2020;24(15):8096-8103. doi: 10.26355/eurrev_202008_22494.Zhou XJ, Zhang X, Zhang J, Zhou L, Zhou TT, Zhang JW. Diagnostic value of growth differentiation factor-15 and β2-microglobulin in children with congenital heart disease combined with chronic heart failure and its relationship with cardiac function. Eur Rev Med Pharmacol Sci. 2020;24(15):8096-8103. doi: 10.26355/eurrev_202008_22494.Berezin AE, Kremzer AA, Berezina TA, Martovitskaya YV. Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: Relevance to neurohumoral and inflammatory activation. BBA Clin. 2015;4:69-75. doi: 10.1016/j.bbacli.2015.07.002.Berezin AE, Kremzer AA, Berezina TA, Martovitskaya YV. Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: Relevance to neurohumoral and inflammatory activation. BBA Clin. 2015;4:69-75. doi: 10.1016/j.bbacli.2015.07.002.Chatterjee NA, Singh JP. Novel Interventional Therapies to Modulate the Autonomic Tone in Heart Failure. JACC Heart Fail. 2015;3(10):786-802. doi: 10.1016/j.jchf.2015.05.008.Chatterjee NA, Singh JP. Novel Interventional Therapies to Modulate the Autonomic Tone in Heart Failure. JACC Heart Fail. 2015;3(10):786-802. doi: 10.1016/j.jchf.2015.05.008.Алиева АМ, Теплова НВ, Воронкова КВ, Пинчук ТВ, Валиев РК, Шнахова ЛМ, Рахаев АМ, Никитин ИГ. Адреномедуллин – биологический маркер сердечной недостаточности: обзор современной литературы. CardioСоматика. 2022;13(1):64-69. doi: 10.17816/22217185.2022.1.20147263. Alieva A M, Teplova N. V., Voronkova KV, Pinchuk TV, Valiev RK, Shnakhova L M, Rakhaeva M, Nikitin AND G. Adrenomedullin – a biological marker of heart failure: a review of modern literature. Cardiosomatics. 2022;13(1):64-69. doi: 10.17816/22217185.2022.1.201472. (In Russian)Hala A., Amal A.M. Study of adrenomedullin in children with heart failure. Alex. J. Pediatr. 2005;19:17.Hala A., Amal A.M. Study of adrenomedullin in children with heart failure. Alex. J. Pediatr. 2005;19:17.Кремнева Л.В. Значение копептина для диагностики инфаркта миокарда. Российский кардиологический журнал. 2017;(11):93-97. doi:10.15829/1560-4071-2017-11-93-9765. Kremneva L.V. The value of copeptin for the diagnosis of myocardial infarction. Russian Journal of Cardiology. 2017;(11):93-97. doi:10.15829/1560-4071-2017-11-93-97 (In Russian)Karki K.B., Towbin J.A., Philip R.R., Harrell C., Tadphale S., Shah S., Saini A. Copeptin: A novel biomarker in pediatric heart failure due to cardiomyopathies. Circulation. 2019;140:A11217Karki K.B., Towbin J.A., Philip R.R., Harrell C., Tadphale S., Shah S., Saini A. Copeptin: A novel biomarker in pediatric heart failure due to cardiomyopathies. Circulation. 2019;140:A11217Elhewala AA, Sanad M, Soliman AM, Sami MM, Ahmed AA. Matrix metalloproteinase-9 in pediatric rheumatic heart disease with and without heart failure. Biomed Rep. 2021;14(1):4. doi: 10.3892/br.2020.1380.Elhewala AA, Sanad M, Soliman AM, Sami MM, Ahmed AA. Matrix metalloproteinase-9 in pediatric rheumatic heart disease with and without heart failure. Biomed Rep. 2021;14(1):4. doi: 10.3892/br.2020.1380.Демко И.В., Собко Е.А., Соловьева И.А., Крапошина А.Ю., Гордеева Н.В., Аникин Д.А. Роль окислительного стресса в патофизиологии кардиоваскулярной патологии. Вестник современной клинической медицины. 2022;1: 107-117. doi: 10.20969/VSKM.2022.15(1).107-117.Demko I.V., Sobko E.A., Solovieva I.A., Kraposhina A.Yu., Gordeeva N.V., Anikin D.A. The role of oxidative stress in the pathophysiology of cardiovascular pathology. Bulletin of Modern Clinical Medicine. 2022;1:107-117. doi: 10.20969/ALL.2022.15(1).107-117. (In Russian).Grassi D, Ferri L, Desideri G, Di Giosia P, Cheli P, Del Pinto R, Properzi G, Ferri C. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des. 2013;19(13):2432-2438. doi: 10.2174/1381612811319130011.Grassi D, Ferri L, Desideri G, Di Giosia P, Cheli P, Del Pinto R, Properzi G, Ferri C. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des. 2013;19(13):2432-2438. doi: 10.2174/1381612811319130011.Krantz M, Klipp E. Moonlighting proteins - an approach to systematize the concept. In Silico Biol. 2020;14(1-2):71-83. doi: 10.3233/ISB-190473.Krantz M, Klipp E. Moonlighting proteins - an approach to systematize the concept. In Silico Biol. 2020;14(1-2):71-83. doi: 10.3233/ISB-190473.Klebanoff SJ, Kettle AJ, Rosen H, Winterbourn CC, Nauseef WM. Myeloperoxidase: a front-line defender against phagocytosed microorganisms. J Leukoc Biol. 2013;93(2):185-198. doi: 10.1189/jlb.0712349.Klebanoff SJ, Kettle AJ, Rosen H, Winterbourn CC, Nauseef WM. Myeloperoxidase: a front-line defender against phagocytosed microorganisms. J Leukoc Biol. 2013;93(2):185-198. doi: 10.1189/jlb.0712349.Ng ML, Ang X, Yap KY, Ng JJ, Goh ECH, Khoo BBJ, Richards AM, Drum CL. Novel Oxidative Stress Biomarkers with Risk Prognosis Values in Heart Failure. Biomedicines. 2023;11(3):917. doi: 10.3390/biomedicines11030917Ng ML, Ang X, Yap KY, Ng JJ, Goh ECH, Khoo BBJ, Richards AM, Drum CL. Novel Oxidative Stress Biomarkers with Risk Prognosis Values in Heart Failure. Biomedicines. 2023;11(3):917. doi: 10.3390/biomedicines11030917Ng LL, Pathik B, Loke IW, Squire IB, Davies JE. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J. 2006;152(1):94-101. doi: 10.1016/j.ahj.2005.09.020.Ng LL, Pathik B, Loke IW, Squire IB, Davies JE. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J. 2006;152(1):94-101. doi: 10.1016/j.ahj.2005.09.020.El-Alameey I.R., Mahmoud R.A., Kairy S.A., Medany E.A. Significance of myeloperoxidase in the onset of cardiovascular disease among obese children and adolescents. Biomed. Pharmacol. J. 2019;12:1647–1659. doi: 10.13005/bpj/1795.El-Alameey I.R., Mahmoud R.A., Kairy S.A., Medany E.A. Significance of myeloperoxidase in the onset of cardiovascular disease among obese children and adolescents. Biomed. Pharmacol. J. 2019;12:1647–1659. doi: 10.13005/bpj/1795

The authors declare that there are no conflicts of interest present.